Clover Health Investments (NASDAQ:CLOV) Stock Crosses Below 50-Day Moving Average – What’s Next?

Shares of Clover Health Investments, Corp. (NASDAQ:CLOV – Get Free Report) passed below its 50-day moving average during trading on Wednesday. The stock has a 50-day moving average of $4.63 and traded as low as $4.11. Clover Health Investments shares last traded at $4.17, with a volume of 8,054,217 shares.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on CLOV. UBS Group boosted their price objective on shares of Clover Health Investments from $5.00 to $5.50 and gave the stock a “neutral” rating in a research report on Thursday, November 5th. Needham & Company LLC reaffirmed a “buy” rating on shares of Clover Health Investments in a research report on Thursday, November 5th. Wall Street Zen downgraded shares of Clover Health Investments from a “strong-buy” rating to a “buy” rating in a research report on Sunday, August 16th. Zacks Research upgraded shares of Clover Health Investments to a “hold” rating in a research note on Monday, September 14th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Clover Health Investments in a research report on Monday, September 21st. Three investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $5.10.

View Our Latest Analysis on CLOV

Clover Health Investments Stock Down 11.8%

The firm has a market capitalization of $2.23 billion, a price-to-earnings ratio of 417.42 and a beta of 2.52. The company has a fifty day moving average price of $4.63 and a two-hundred day moving average price of $3.68.

Clover Health Investments (NASDAQ:CLOV – Get Free Report) last announced its earnings results on Wednesday, November 4th. The company reported $0.01 EPS for the quarter, beating analysts’ consensus estimates of ($0.01) by $0.02. The business had revenue of $759.30 million for the quarter, compared to analysts’ expectations of $740.07 million. Clover Health Investments had a net margin of 0.45% and a return on equity of 4.66%. On average, equities analysts anticipate that Clover Health Investments, Corp. will post 0.06 earnings per share for the current fiscal year.

Insider Buying and Selling at Clover Health Investments

In other news, CEO Conrad Wai sold 300,000 shares of the company’s stock in a transaction dated Tuesday, September 15th. The shares were sold at an average price of $4.72, for a total value of $1,416,000.00. Following the completion of the sale, the chief executive officer directly owned 1,170,056 shares of the company’s stock, valued at approximately $5,522,664.32. This represents a 20.41% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Andrew Toy sold 318,806 shares of the stock in a transaction dated Thursday, October 1st. The stock was sold at an average price of $4.19, for a total transaction of $1,335,797.14. Following the sale, the chief executive officer owned 9,140,510 shares of the company’s stock, valued at $38,298,736.90. This trade represents a 3.37% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders have sold 768,573 shares of company stock valued at $3,462,479. Company insiders own 23.51% of the company’s stock.

Institutional Trading of Clover Health Investments

A number of hedge funds have recently added to or reduced their stakes in the stock. Goldman Sachs Group Inc. grew its stake in shares of Clover Health Investments by 40.4% in the 3rd quarter. Goldman Sachs Group Inc. now owns 1,643,899 shares of the company’s stock valued at $7,085,000 after purchasing an additional 473,157 shares during the last quarter. Bank of New York Mellon Corp purchased a new stake in shares of Clover Health Investments during the second quarter worth approximately $6,346,000. Tidal Investments LLC acquired a new stake in shares of Clover Health Investments during the second quarter worth $2,156,000. Algert Global LLC lifted its holdings in shares of Clover Health Investments by 6.2% during the third quarter. Algert Global LLC now owns 398,440 shares of the company’s stock worth $1,717,000 after purchasing an additional 23,360 shares during the period. Finally, WINTON GROUP Ltd acquired a new stake in shares of Clover Health Investments during the second quarter worth $913,000. 19.77% of the stock is owned by institutional investors and hedge funds.

About Clover Health Investments

(Get Free Report)

Clover Health Investments is a U.S. healthcare company focused on Medicare. Its insurance business offers Medicare Advantage plans to eligible beneficiaries in select markets, combining medical coverage with support intended to help members access care. The company also developed the Clover Assistant, a technology platform that organizes patient information and provides clinicians with insights to support care decisions. Clover has described the platform as a way to help primary care providers identify health needs and coordinate care for people with complex conditions.

Further Reading

Receive News & Ratings for Clover Health Investments Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clover Health Investments and related companies with MarketBeat.com's FREE daily email newsletter.